Altered purinergic receptor expression in the frontal cortex in schizophrenia

ATP functions as a neurotransmitter, acting on the ubiquitously expressed family of purinergic P2 receptors. In schizophrenia (SCZ), the pathways that modulate extracellular ATP and its catabolism to adenosine are dysregulated. However, the effects of altered ATP availability on P2 receptor expressi...

Full description

Saved in:
Bibliographic Details
Published in:NPJ schizophrenia 2022-11, Vol.8 (1), p.96-96, Article 96
Main Authors: Alnafisah, Rawan, Lundh, Anna, Asah, Sophie M., Hoeflinger, Julie, Wolfinger, Alyssa, Hamoud, Abdul-rizaq, McCullumsmith, Robert E., O’Donovan, Sinead M.
Format: Article
Language:English
Subjects:
631/378/1689/1799
631/378/340
Cognitive Psychology
Medicine
Medicine & Public Health
Neurology
Neurosciences
Psychiatry
Schizophrenia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ATP functions as a neurotransmitter, acting on the ubiquitously expressed family of purinergic P2 receptors. In schizophrenia (SCZ), the pathways that modulate extracellular ATP and its catabolism to adenosine are dysregulated. However, the effects of altered ATP availability on P2 receptor expression in the brain in SCZ have not been assessed. We assayed P2 receptor mRNA and protein expression in the DLPFC and ACC in subjects diagnosed with SCZ and matched, non-psychiatrically ill controls ( n  = 20–22/group). P2RX7, P2RX4 and male P2RX5 mRNA expression were significantly increased ( p  
ISSN:2754-6993
2754-6993
2334-265X
DOI:10.1038/s41537-022-00312-1